Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

withdrawn125%
recruiting125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_1

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

NCT02291848
completedphase_2

TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

NCT03093350
withdrawnphase_1

(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).

NCT05134740
completedphase_1

TAA-Specific CTLS for Solid Tumors (TACTASOM)

NCT02239861

Clinical Trials (4)

Showing 4 of 4 trials
NCT02291848Phase 1

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

Recruiting
NCT03093350Phase 2

TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

Completed
NCT05134740Phase 1

(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).

Withdrawn
NCT02239861Phase 1

TAA-Specific CTLS for Solid Tumors (TACTASOM)

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4